Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 24k
26 July 2018
Answer given by Mr Andriukaitis on behalf of the European Commission
Question reference: E-002999/2018

On 25 April 2018, the Commission adopted a communication on digital health and care(1), which includes a key section on better data to promote research, disease prevention and personalised health and care. In the communication, the Commission presents, as area for piloting, the use of real-world data by healthcare professionals, public authorities and industry to ensure that healthcare products, innovative technologies and therapies meet patients' needs and lead to favourable health outcomes.

The Commission aims to take this pilot forward, by leveraging existing work and optimizing use of real-world data by researchers, healthcare professionals, health technology assessment agencies, regulatory and other public authorities. Therefore as a first step, the Commission will take into account the existing programmes and ongoing initiatives in the field such as Horizon 2020 and Innovative Medicines Initiative research projects, EUnetHTA(2) and GAPP Joint Actions(3), projects led by the European Medicines Agency and feedback from all relevant stakeholders. Objectives will be to improve the common understanding on how the value of real-world data can be best captured and to provide practical guidance for its use.


Last updated: 7 August 2018Legal notice - Privacy policy